Impact of the Structures of Macrocyclic Michael Acceptors on Covalent Proteasome Inhibition

Overview

Journal Chem Sci

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2017 Nov 18

PMID 29147522

Citations 4

Authors

S Kitahata

F Yakushiji

S Ichikawa

Affiliations

Soon will be listed here.

Abstract

Molecules that have a reactive functional group within a macrocycle represent a class of covalent inhibitor. The relationship between reactivity and affinity for the target is cooperative and complicated. An understanding and characterization of this class of inhibitor are vital for the development of covalent inhibitors as drug candidates. Herein, we describe a systematic analysis of structure-activity relationships using a series of syringolin analogues, which are irreversible covalent inhibitors of proteasomes. We investigate the detailed mechanistic effects of the macrocycles on affinity and reaction rate.

Citing Articles

Comprehensive Structure-Activity Relationship Studies of Cepafungin Enabled by Biocatalytic C-H Oxidations.

Amatuni A, Shuster A, Abegg D, Adibekian A, Renata H ACS Cent Sci. 2023; 9(2):239-251.

PMID: 36844499 PMC: 9951290. DOI: 10.1021/acscentsci.2c01219.

Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study.

Hatmal M, Abuyaman O, Taha M Comput Struct Biotechnol J. 2021; 19:4790-4824.

PMID: 34426763 PMC: 8373588. DOI: 10.1016/j.csbj.2021.08.023.

Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I.

Amatuni A, Shuster A, Adibekian A, Renata H Cell Chem Biol. 2020; 27(10):1318-1326.e18.

PMID: 32763140 PMC: 8201661. DOI: 10.1016/j.chembiol.2020.07.012.

Identification of a lysine 4-hydroxylase from the glidobactin biosynthesis and evaluation of its biocatalytic potential.

Amatuni A, Renata H Org Biomol Chem. 2018; 17(7):1736-1739.

PMID: 30320324 PMC: 6374188. DOI: 10.1039/c8ob02054j.

References

Nelson V, Ziehr J, Agulnik M, Johnson M . Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013; 6:135-43. PMC: 3594037. DOI: 10.2147/OTT.S23165. View

Singh J, Petter R, Kluge A . Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010; 14(4):475-80. DOI: 10.1016/j.cbpa.2010.06.168. View

Pirrung M, Biswas G, Ibarra-Rivera T . Total synthesis of syringolin A and B. Org Lett. 2010; 12(10):2402-5. DOI: 10.1021/ol100761z. View

Potashman M, Duggan M . Covalent modifiers: an orthogonal approach to drug design. J Med Chem. 2009; 52(5):1231-46. DOI: 10.1021/jm8008597. View

Fenteany G, Standaert R, Lane W, Choi S, Corey E, Schreiber S . Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995; 268(5211):726-31. DOI: 10.1126/science.7732382. View

Singh J, Dobrusin E, FRY D, Haske T, Whitty A, McNamara D . Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J Med Chem. 1997; 40(7):1130-5. DOI: 10.1021/jm960380s. View

Liebler D . Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol. 2007; 21(1):117-28. PMC: 2533766. DOI: 10.1021/tx700235t. View

Singh J, Petter R, Baillie T, Whitty A . The resurgence of covalent drugs. Nat Rev Drug Discov. 2011; 10(4):307-17. DOI: 10.1038/nrd3410. View

Lanning B, Whitby L, Dix M, Douhan J, Gilbert A, Hett E . A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat Chem Biol. 2014; 10(9):760-767. PMC: 4138289. DOI: 10.1038/nchembio.1582. View

10.

Uetrecht J . Immune-mediated adverse drug reactions. Chem Res Toxicol. 2009; 22(1):24-34. DOI: 10.1021/tx800389u. View

11.

Bauer R . Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today. 2015; 20(9):1061-73. DOI: 10.1016/j.drudis.2015.05.005. View

12.

Kitahata S, Chiba T, Yoshida T, Ri M, Iida S, Matsuda A . Design, Synthesis, and Biological Activity of Isosyringolin A. Org Lett. 2016; 18(9):2312-5. DOI: 10.1021/acs.orglett.6b01053. View

13.

Kluge A, Petter R . Acylating drugs: redesigning natural covalent inhibitors. Curr Opin Chem Biol. 2010; 14(3):421-7. DOI: 10.1016/j.cbpa.2010.03.035. View

14.

Ahn K, Johnson D, Mileni M, Beidler D, Long J, McKinney M . Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009; 16(4):411-20. PMC: 2692831. DOI: 10.1016/j.chembiol.2009.02.013. View

15.

Archer C, Koomoa D, Mitsunaga E, Clerc J, Shimizu M, Kaiser M . Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma. Biochem Pharmacol. 2010; 80(2):170-8. DOI: 10.1016/j.bcp.2010.03.031. View

16.

Dai C, Stephenson C . Total synthesis of syringolin A. Org Lett. 2010; 12(15):3453-5. DOI: 10.1021/ol101252y. View

17.

Chiba T, Matsuda A, Ichikawa S . Structure-activity relationship study of syringolin A as a potential anticancer agent. Bioorg Med Chem Lett. 2015; 25(21):4872-4877. DOI: 10.1016/j.bmcl.2015.06.015. View

18.

Rajashekhar B, FITZPATRICK P, Colombo G, Villafranca J . Synthesis of several 2-substituted 3-(p-hydroxyphenyl)-1-propenes and their characterization as mechanism-based inhibitors of dopamine beta-hydroxylase. J Biol Chem. 1984; 259(11):6925-30. View

19.

Lee C, Grossmann T . Reversible covalent inhibition of a protein target. Angew Chem Int Ed Engl. 2012; 51(35):8699-700. DOI: 10.1002/anie.201203341. View

20.

Giordano P, Manzo A, Montanino A, Costanzo R, Sandomenico C, Piccirillo M . Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. Crit Rev Oncol Hematol. 2015; 97:143-51. DOI: 10.1016/j.critrevonc.2015.08.016. View